Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 5, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Ultra high-risk myeloma.

Hervé Avet-Loiseau1

  • 1Laboratoire d'Hématologie, Institut de Biologie, Nantes, France. herve.avetloiseau@chu-nantes.fr

Hematology. American Society of Hematology. Education Program
|January 18, 2011
PubMed
Summary

Ultra high-risk myeloma patients face a grim prognosis, often leading to death within 24 months. Novel therapies offer hope, but identifying and treating these challenging multiple myeloma cases requires tailored strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Blood cancer journal·2026
Same author

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Blood·2026
Same author

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Blood advances·2026
Same author

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Nature medicine·2026
Same author

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

Cell reports·2025

Area of Science:

  • Hematology
  • Oncology
  • Medical Research

Background:

  • Ultra high-risk myeloma, defined by a 24-month mortality, constitutes 15-20% of patients despite recent therapeutic advances.
  • Novel agents like thalidomide, bortezomib, and lenalidomide have improved outcomes but not eliminated the challenge of ultra high-risk myeloma.

Purpose of the Study:

  • To define ultra high-risk myeloma based on prognostic factors.
  • To explore potential therapeutic strategies for fit patients with ultra high-risk myeloma.

Main Methods:

  • Review of prognostic factors including age, renal function, performance status, comorbidities, International Staging System (ISS) stage, proliferation rate, leukemic presentation, and genetic abnormalities.
  • Analysis of combinations of prognostic parameters to identify ultra high-risk patient subgroups.

Main Results:

  • Prognostic factors such as ISS stage 3, high proliferation, and adverse genetic changes are key indicators of ultra high-risk myeloma.
  • The heterogeneity of prognostic factors makes a universal therapeutic approach challenging.

Conclusions:

  • Ultra high-risk myeloma patients, particularly fit individuals with ISS 3, high proliferation, and poor-risk genetics, may benefit from intensified, prolonged treatment regimens.
  • Inclusion in prospective clinical trials is recommended for optimizing treatment strategies in this patient population.

Related Experiment Videos

Last Updated: Jun 5, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019